private financing

The company said it will use the funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform.

The financing will go toward building out its sales teams in the US and Europe in order to market its multiplexed MDx tests for infectious diseases.

The Redwood, California-based company plans to use the funding to drive the commercial launch of its semiconductor chip-based sequencing-by-synthesis instrument.

The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.

The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.

The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.

The San Diego-based company plans to use the proceeds from the financing to enhance its Health Nucleus intelligence platform.

The  firm will use the net proceeds for research and development, marketing, and general corporate purposes to help commercialize its LX Analyzer technology.

Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.

The company offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.